期刊
CURRENT PHARMACEUTICAL DESIGN
卷 9, 期 14, 页码 1095-1106出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612033454991
关键词
rheumatoid arthritis; cytokine; monoclonal antibody; TNF alpha; IL-1; disease modification; infliximab; etanercept; adalimumab; anakinra
The treatment approach to rheumatoid arthritis has undergone a major evolutionary change e in recent,Cars in part as a consequence of growing appreciation of the severity of this condition and in part due to very considerable progress in understanding the important role of cytokines in die immunopathogenesis of this disease. The major focus of this review is oil the rationale for targeting TNFalpha and IL-1 in rheumatoid arthritis and the results of clinical studies designed to assess the validity of this therapeutic approach. Recently published studies confirm that the long term use of a several biological agents targeting TNFalpha give rise to sustained improvements in symptoms and signs of rheumatoid disease and furthermore, that TNFalpha blockade protects joints from structural damage. Although these drugs are well tolerated and have a good over-all safety profile, pitfalls to the use of anti-TNFalpha agents apparent villi increasing clinical experience include rare cases of tuberculosis. The mechanism of action of anti-TNFalpha therapy is discussed. Clinical trials of interleukin-1 receptor antagonist show relatively modest anti-inflammatory eifficacy and an effect on X-ray indicative joint damage. Other pro-inflammatory cytokines representing potential therapeutic targets include of retardation of interferon-beta, interferon-gamma, IL6, IL-15, IL17 and IL-18. I will consider preliminary data, where available, arising from clinical trials designed to inhibit the activity Of such molecules. Ill this review I Will also discuss the rationale and preliminary data tor other potential therapeutic strategies designed to augment the activity of anti-inflammatory cytokines such as IL-4, IL-10, and IL-11 in rheumatoid disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据